STAT+: Licensing deals on generic versions of Roche flu drug aimed at preparing for pandemic — SkimNews
Get the Health newsletter
Daily health & science — research, biotech, public health, the studies worth knowing. Free.
- Medicines Patent Pool signed sub-licensing deals with 11 manufacturers to develop, manufacture, and supply generic versions of Roche's Xofluza influenza treatment, framed by the source as a pandemic preparedness move.
- The agreements cover 129 countries, described as nearly all low- and middle-income countries, leaving higher-income markets outside the deal's scope.
- The 11 manufacturers receive technical data, reference products for bioequivalence studies, and other support intended to help secure regulatory approval in covered countries.
- Xofluza is Roche's influenza treatment and the product being sub-licensed — the source identifies this as the latest effort to widen medication access for poor countries.
- The source frames the arrangement within an ongoing tension between the pharmaceutical industry's financial priorities and the goal of affordable access for the largest number of patients.
Why it matters: By pre-positioning 11 generic manufacturers with the recipe and regulatory support for Xofluza now, the Medicines Patent Pool aims to avoid the scramble and price spikes that followed past pandemic outbreaks. The 129-country scope excludes wealthier markets where Roche retains exclusivity, trading some patent revenue for broader global preparedness.
Ask SkimNews
